HomeCompareDUVNF vs MRK

DUVNF vs MRK: Dividend Comparison 2026

DUVNF yields 1548.59% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DUVNF wins by $938544519.45M in total portfolio value
10 years
DUVNF
DUVNF
● Live price
1548.59%
Share price
$0.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$938544519.50M
Annual income
$832,760,015,025,041.90
Full DUVNF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — DUVNF vs MRK

📍 DUVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDUVNFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DUVNF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DUVNF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DUVNF
Annual income on $10K today (after 15% tax)
$131,629.89/yr
After 10yr DRIP, annual income (after tax)
$707,846,012,771,285.60/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, DUVNF beats the other by $707,846,012,762,957.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DUVNF + MRK for your $10,000?

DUVNF: 50%MRK: 50%
100% MRK50/50100% DUVNF
Portfolio after 10yr
$469272259.78M
Annual income
$416,380,007,517,420.00/yr
Blended yield
88.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DUVNF
No analyst data
Altman Z
1.8
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DUVNF buys
0
MRK buys
0
No recent congressional trades found for DUVNF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDUVNFMRK
Forward yield1548.59%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$938544519.50M$56.8K
Annual income after 10y$832,760,015,025,041.90$9,798.13
Total dividends collected$930867489.67M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DUVNF vs MRK ($10,000, DRIP)

YearDUVNF PortfolioDUVNF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$165,559$154,858.69$11,206$366.19+$154.4KDUVNF
2$2,573,241$2,396,093.67$12,650$502.35+$2.56MDUVNF
3$37,558,924$34,805,555.72$14,407$694.19+$37.54MDUVNF
4$514,973,492$474,785,443.27$16,585$967.82+$514.96MDUVNF
5$6,634,967,613$6,083,945,976.33$19,342$1,363.89+$6634.95MDUVNF
6$80,357,490,596$73,258,075,250.06$22,913$1,947.19+$80357.47MDUVNF
7$915,182,499,203$829,199,984,265.06$27,662$2,823.89+$915182.47MDUVNF
8$9,805,101,490,263$8,825,856,216,115.94$34,159$4,173.35+$9805101.46MDUVNF
9$98,864,022,876,689$88,372,564,282,107.62$43,337$6,308.80+$98864022.83MDUVNF
10$938,544,519,503,099$832,760,015,025,041.90$56,776$9,798.13+$938544519.45MDUVNF

DUVNF vs MRK: Complete Analysis 2026

DUVNFStock

Peruvian Metals Corp. engages in the acquisition, exploration for, and development of precious and base metals in Peru. The company holds 100% interests in the Panteria Porphyry Gold - Copper Project that consists of 4 mineral concessions covering an area of 2,000 hectares in south-central Peru; and the Cerro La Cumbre project consists of 2 mineral concessions covering an area of 727 hectares. It also has interests in the Huachocolpa properties that consist of 78 contiguous and non-contiguous mining concessions covering an area of 2,548 hectares located in the Department of Huancavelica; and the Palta Dorada property, which covers an area of 1,200 hectares located in the Ancash Mining Department in northern Peru; the Indio Inka property, which covers an area of 470 hectares located in asphalted road from the Aguila Norte processing plant; and the Minas Yanayco, which covers an area of 500 hectares located in Ancash Department near the small town of Pueblo Libre, as well as the Minas Visca project in northern Peru that covers an area of approximately 94 hectares. The company was formerly known as Duran Ventures Inc. and changed its name to Peruvian Metals Corp. in September 2018. Peruvian Metals Corp. was incorporated in 1997 and is based in Edmonton, Canada.

Full DUVNF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DUVNF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DUVNF vs SCHDDUVNF vs JEPIDUVNF vs ODUVNF vs KODUVNF vs MAINDUVNF vs JNJDUVNF vs ABBVDUVNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.